全文获取类型
收费全文 | 35381篇 |
免费 | 3406篇 |
国内免费 | 397篇 |
专业分类
耳鼻咽喉 | 328篇 |
儿科学 | 2052篇 |
妇产科学 | 389篇 |
基础医学 | 3910篇 |
口腔科学 | 532篇 |
临床医学 | 3113篇 |
内科学 | 2503篇 |
皮肤病学 | 220篇 |
神经病学 | 14927篇 |
特种医学 | 323篇 |
外科学 | 1100篇 |
综合类 | 2702篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 3026篇 |
眼科学 | 127篇 |
药学 | 2870篇 |
7篇 | |
中国医学 | 841篇 |
肿瘤学 | 211篇 |
出版年
2024年 | 102篇 |
2023年 | 854篇 |
2022年 | 1048篇 |
2021年 | 1831篇 |
2020年 | 1738篇 |
2019年 | 1649篇 |
2018年 | 1528篇 |
2017年 | 1610篇 |
2016年 | 1659篇 |
2015年 | 1442篇 |
2014年 | 2385篇 |
2013年 | 3319篇 |
2012年 | 1857篇 |
2011年 | 2275篇 |
2010年 | 1756篇 |
2009年 | 1766篇 |
2008年 | 1795篇 |
2007年 | 1648篇 |
2006年 | 1353篇 |
2005年 | 1136篇 |
2004年 | 924篇 |
2003年 | 838篇 |
2002年 | 730篇 |
2001年 | 521篇 |
2000年 | 421篇 |
1999年 | 365篇 |
1998年 | 405篇 |
1997年 | 325篇 |
1996年 | 249篇 |
1995年 | 206篇 |
1994年 | 174篇 |
1993年 | 160篇 |
1992年 | 160篇 |
1991年 | 152篇 |
1990年 | 126篇 |
1989年 | 121篇 |
1988年 | 107篇 |
1987年 | 82篇 |
1986年 | 44篇 |
1985年 | 78篇 |
1984年 | 50篇 |
1983年 | 32篇 |
1982年 | 53篇 |
1981年 | 30篇 |
1980年 | 19篇 |
1979年 | 18篇 |
1978年 | 13篇 |
1977年 | 12篇 |
1976年 | 7篇 |
1974年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
目的 探讨以行为-结构化-关系(BSR)干预模式对短期住院孤独症谱系障碍(ASD)儿童的干预疗效,为改善ASD儿童的预后提供参考依据。方法 选取2015年12月-2016年12月确诊为ASD的2~6岁儿童141例,随机分为治疗组和对照组。治疗组ASD儿童均接受BSR模式的短期课程训练,训练课程包括个别辅导、游戏课、运动课、音乐课等,每天训练时间6 h,持续1个月;对照组ASD儿童处于干预等待,接受随访观察和评估。所有ASD儿童干预前、后均接受儿童心理教育评估(第三版)(PEP-3)来进行各方面能力变化的评估。结果 治疗组、对照组干预前各副测验的原积分差异无统计学意义(P>0.05)。两组ASD儿童干预后认知、语言理解、模仿、情感表达、社会互动、行为特征-非语言、适应行为的原积分比较,差异均有统计学意义(t=2.41、2.02、4.14、3.69、4.42、2.69、2.96,P<0.05);但小肌肉、大肌肉、自理的原积分比较,差异无统计学意义(t=-1.13、-1.05、-0.84,P>0.05)。结论 BSR干预模式能够有效改善短期住院ASD儿童的预后,可推广用于儿童ASD的治疗。 相似文献
22.
23.
孤独症谱系障碍(ASD)的核心诊断特征是社会交流障碍以及受限和重复的行为和兴趣,症状常在生命的最初几年出现。过去的二十年内,神经成像揭示了许多“社会性”大脑的非典型活动和异常连通性的发现,包括梭状回对面部和凝视的分析、杏仁核的情绪处理、默认模式网络的心智化以及镜像神经元相关区域对他人行为的模仿和理解,但对于社交功能缺陷潜在的神经生理机制还未达成一致。除了方法学上的挑战以及聚焦于单个大脑网络的连通性研究以外,更深层次的问题是ASD的极强异质性。这种不一致的发现,可能是由于诊断标准的变化以及学龄前期的ASD患儿存在非典型的神经发育轨迹,因此,有必要进行孤独症亚型的队列研究和大样本的纵向队列研究。 相似文献
24.
25.
Mt D. Dbrssy Chockalingam Ramanathan Danesh Ashouri Vajari Yixin Tong Thomas Schlaepfer Volker A. Coenen 《The European journal of neuroscience》2021,53(1):89-113
Deep brain stimulation (DBS) in psychiatric illnesses has been clinically tested over the past 20 years. The clinical application of DBS to the superolateral branch of the medial forebrain bundle in treatment‐resistant depressed patients—one of several targets under investigation—has shown to be promising in a number of uncontrolled open label trials. However, there are remain numerous questions that need to be investigated to understand and optimize the clinical use of DBS in depression, including, for example, the relationship between the symptoms, the biological substrates/projections and the stimulation itself. In the context of precision and customized medicine, the current paper focuses on clinical and experimental research of medial forebrain bundle DBS in depression or in animal models of depression, demonstrating how clinical and scientific progress can work in tandem to test the therapeutic value and investigate the mechanisms of this experimental treatment. As one of the hypotheses is that depression engenders changes in the reward and motivational networks, the review looks at how stimulation of the medial forebrain bundle impacts the dopaminergic system. 相似文献
26.
27.
28.
29.
30.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.